MAPT and Alzheimer disease: As a result, tau PET imaging showed superior diagnostic validity to CSF tau biomarkers in AD (Mattsson et al., 2018) and correlated with CSF tau levels and cognitive deficits (Saint-Aubert et al., 2016; Bejanin et al., 2017; Chiotis et al., 2018; La Joie et al., 2018).